Showing 2411-2420 of 5065 results for "".
Novel Treatments for Acne
https://practicaldermatology.com/topics/acne-rosacea/novel-treatments-for-acne/19761/Joshua Zeichner, MD discusses three new treatments now available in the acne treatment armamentarium. For patients with severe acne, a new low-dose isotretinoin in a micronized formulation allows for better absorption, even without food. Dr. Zeichner also discusses the benefits of a new topical retiSpecial Report: COVID-19 Impact and Response
https://practicaldermatology.com/topics/practice-management/special-report-covid-19-impact-and-response/19752/The COVID-19 pandemic is causing a halt in elective surgeries and forcing dermatology and aesthetics practices to temporarily close. Hear from those affected. Telemedicine is expanding in response to patient needs, as OCR addresses HIPAA enforcement. Learn about enforcement and new technology optionDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treNoah Worcester 2024: Dr. Bettencourt on Beach Vacations
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bettencourt-beach-vacations/24591/Miriam Bettencourt, MD, summarizes her lecture about problems that can be encountered during beach vacations at the 2024 Noah Worcester Dermatological Society meeting.Five ways to market for the “next normal”
https://practicaldermatology.com/topics/practice-management/five-ways-to-market-for-the-next-normal/20015/You’ve heard it time and time again. The “new normal.” We have been living and working within this new environment for almost two years. In this Ekwa Marketing video, we ask, “What is the next normal?” We isolate five ways to market for tomorrow’s increasingly digitally savvy, curious, socially awarDermWireTV: Impact of COVID-19 on Dermatology
https://practicaldermatology.com/topics/practice-management/dermwiretv-impact-of-covid-19-on-dermatology/19878/As COVID-19 infections surge across the US, a vaccine has been approved. What's it mean for dermatology patients? And how is the pandemic impacting dermatology practices? Updates from the International Psoriasis Council; Mark Nestor, MD; Amy Taub, MD; Terrence Keaney, MD; and Melissa Kanchanapoomi LThe Benjamin Button Effect: Noninvasive Rejuvenation
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-benjamin-button-effect-noninvasive-rejuvenation/18813/Heidi Waldorf, MD explains her approach to helping patients achieve the best, most natural results from noninvasive rejuvenation. She says her patients want to look like themselves after aesthetic treatment—but a healthier, more youthful version of themselves. Dr. Waldorf shares tips for interactingMechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://practicaldermatology.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,Differentiating Prurigo Nodularis Lesions
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/differentiating-prurigo-nodularis-lesions/48787/James Q. Del Rosso, DO, FAOCD, discusses clinical pearls to help distinguish prurigo nodularis from other pruritic dermatoses during initial evaluation.Dermwire TV: Ruxolitinib Cream 1.5% Effective for AD Improvement, Stapokibart Shows Promise
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-ruxolitinib-cream-15-effective-for-ad-improvement-stapokibart-shows-promise/49101/This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research valida